Equibles does not estimate personal net worth.
Get an email with a short summary when Alnylam Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get ALNY alertsJeffrey Poulton is recorded as CFO at Alnylam Pharmaceuticals, Inc. (ALNY). The newest filing on record that lists Jeffrey Poulton as CFO at Alnylam Pharmaceuticals, Inc. (ALNY) is dated April 1, 2024. The proxy statement of Alnylam Pharmaceuticals, Inc. reports total compensation of $6,863,800 for Jeffrey Poulton in fiscal 2025, including a base salary of $724,400. Disclosed compensation is on record for 7 fiscal years. Jeffrey Poulton has spoken on 27 earnings calls across 1 company, most recently for Alnylam Pharmaceuticals, Inc. on October 29, 2026. Alnylam Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Alnylam Pharmaceuticals, Inc. includes Yvonne Greenstreet (CEO and COO), Yvonne L. Greenstreet (CEO, COO and Board Member), Amy W. Schulman (Chairman and Board Member) and 7 others.
“I'll be presenting the summary of Alnylam's third quarter 2026 financial results and discussing our outlook for the balance of the year. Let's begin with a summary of our P&L results for the third quarter.”
“This morning, I'll be presenting a summary of El Nilem's second quarter of 2026 financial results and discussing updates to our full-year guidance. Let's begin with the summary of our P&L results for the second quarter.”
“I'm pleased to be presenting a summary of Alnylam's first quarter 2026 financial results and discussing our full-year guidance. Let's begin with a summary of our P&L results for Q1 2026.”
“I'm pleased to be presenting a summary of Alnylam's full year 2025 financial results and providing our comprehensive financial guidance for 2026. Let's begin with a summary of our P&L results for the full year.”
“I'm pleased to be presenting a summary of Alnylam's Q3 2025 financial results and discussing our full year upgraded guidance. Let's begin with a summary of our P&L results for Q3 2025 compared with the same period in 2024.”
Start not stated–present
Last confirmed April 1, 2024
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Alnylam Pharmaceuticals, Inc. (ALNY) | Executive Vice President, Chief Financial Officer (principal financial officer) | $724,400 | $6,863,800 |
| 2024 | Alnylam Pharmaceuticals, Inc. (ALNY) | Executive Vice President, Chief Financial Officer (principal financial officer) | $687,400 | $3,792,780 |
| 2023 | Alnylam Pharmaceuticals, Inc. (ALNY) | Executive Vice President, Chief Financial Officer (principal financial officer) | $651,900 | $3,224,360 |
| 2022 | Alnylam Pharmaceuticals, Inc. (ALNY) | Executive Vice President, Chief Financial Officer (principal financial officer) | $604,500 | $2,421,630 |
| 2021 | Alnylam Pharmaceuticals, Inc. (ALNY) | Executive Vice President, Chief Financial Officer (principal financial officer) | $569,200 | $2,798,175 |
| 2020 | Alnylam Pharmaceuticals, Inc. (ALNY) | Executive Vice President, Chief Financial Officer (principal financial officer) | $556,800 | $2,492,968 |
| 2019 | Alnylam Pharmaceuticals, Inc. (ALNY) | Executive Vice President, ChiefFinancial Officer (principal financial officer) | $254,808 | $5,877,416 |
